Close
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Apr 26 2024 12:00
    73,730.16 -609.28 (-0.82%)
  • NIFTY Apr 26 2024 12:00
    22,419.95 -150.40 (-0.67%)
  • SENSEX Apr 26 2024 12:00
    73,730.16 -609.28 (-0.82%)
  • NIFTY Apr 26 2024 12:00
    22,419.95 -150.40 (-0.67%)
  • Nasdaq Apr 27 2024 04:30
    15,927.90 +316.14 ( +2.03%)
  • DJIA Apr 27 2024 04:30
    38,239.66 +153.86 ( +0.40%)
  • S&P 500 Apr 27 2024 04:30
    5,099.96 +51.54 ( +1.02%)
  • Hang Seng Apr 26 2024 02:10
    17,651.15 +366.61 ( +2.12%)
  • Crude Oil Apr 26 2024 11:29
    6,995.00 -4.00 (-0.06%)
  • Gold Apr 26 2024 11:29
    71,486.00 -14.00 (-0.02%)
  • Silver Apr 26 2024 11:29
    80,745.00 +65.00 ( +0.08%)
  • Copper Apr 26 2024 11:29
    859.50 +11.10 ( +1.31%)
  • Pound / Rupee Dec 23 2016 22:30
    104.10 +0.39 ( +0.38%)
  • Dollar / Rupee Dec 23 2016 22:30
    83.32 +0.01 ( +0.01%)
  • Euro / Rupee Dec 23 2016 22:30
    89.30 +0.19 ( +0.22%)
  • Yen / Rupee Dec 23 2016 22:30
    0.54 0.00 (-0.34%)

BSE Code : | NSE Symbol : | ISIN:| SECTOR : |

NSE BSE
 

Volume

Prev. Close

Open Price

Bid Price (QTY)

Offer Price (QTY)

 

Today’s High/Low -

52 wk High/Low -

Key Stats

MARKET CAP (RS CR) 212.12
P/E 40.21
BOOK VALUE (RS) 33.6195885
DIV (%) 0
MARKET LOT 1
EPS (TTM) 4.19
PRICE/BOOK 5.011959025019
DIV YIELD.(%) 0
FACE VALUE (RS) 10
DELIVERABLES (%)
4

News & Announcements

15-Feb-2024

Lactose (India) standalone net profit rises 1778.57% in the December 2023 quarter

06-Feb-2024

Lactose (India) to discuss results

25-Jan-2024

Lactose (India) Ltd - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

09-Jan-2024

Lactose (India) Ltd - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

06-Feb-2024

Lactose (India) to discuss results

25-Oct-2023

Lactose (India) to declare Quarterly Result

18-Aug-2023

Lactose (India) to convene AGM

08-Aug-2023

Lactose (India) to discuss results

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Aarey Drugs & Pharmaceuticals Ltd 524412 AAREYDRUGS
Aarti Drugs Ltd 524348 AARTIDRUGS
Add Life Pharma Ltd 524665
Adithya Alkaloids Pvt Ltd 524320
Alpha Drug India Ltd(merged) 500006 ALPHADRUG
Ami Organics Ltd 543349 AMIORG
Anuh Pharma Ltd 506260
Anus Laboratories Ltd 532981
Arch Pharmalabs Ltd 524729
Aster Drugs & Pharmaceuticals Ltd 40286
Auro Laboratories Ltd 530233
Auromed Ltd 532103
Bacil Pharma Ltd 524516
Beta Drugs Ltd 535022 BETA
Betalact Laboratories Ltd 531238
Biotech Synergy Ltd 40183
Cheminor Drugs Ltd (Merged) 524140 CHEMNODRUG
Chemo Pharma Laboratories Ltd 506365
Chemox Chemical Industries Ltd (Wound-up) 512042 CHEMOXCHEM
Chiplun Fine Chemicals Ltd 530417
Core Laboratories Ltd (Merged) 506963
Coromandel Pharmaceuticals Ltd 524524
Daurala Organics Ltd(merged) 524256 DAURALAORG
Dishman Pharmaceuticals and Chemicals Ltd(Merged) 532526 DISHMAN
Divis Laboratories Ltd 532488 DIVISLAB
Dynachem Pharmaceuticals (Export) Ltd 524562 DYNAPHARMA
Elder Pharmaceuticals Ltd 532322 ELDERPHARM
Elegant Pharmaceuticals Ltd 524344
Emergy Phaarma Ltd 524812
Everest Organics Ltd 524790
Fermenta Biotech Ltd 506414
Fernhill Industries Ltd 531466
Fine Drugs And Chemicals Ltd (Merged) 524782
Gennex Laboratories Ltd 531739
Gennex Laboratories Ltd Partly Paidup 890171
Godavari Drugs Ltd 530317
Gujarat Lyka Organics Ltd (Merged) 506930
Gujarat Themis Biosyn Ltd 506879 GUJTHEMIS
Hallmark Drugs & Chemicals Ltd 531407
Harshita Ltd 531347
Hikal Ltd 524735 HIKAL
Hiran Orgochem Ltd 506170
Hi-Tech Drugs Ltd 524424
Infinium Pharmachem Ltd 78690 INFINIUM
Ishita Drugs & Industries Ltd 524400
J K Pharmachem Ltd 500218 JKPHARMA
Janak Intermediates Ltd 524380
Jubilant Pharmova Ltd 530019 JUBLPHARMA
Kaprinas Pharmaceuticals & Chemicals Ltd 530147
Kimia Biosciences Ltd 530313
Konar Organics Ltd 526933
Krebs Biochemicals & Industries Ltd 524518 KREBSBIO
Larite Industries Ltd 512325
Magnum Intermediates Ltd 40177
Manav Pharma Ltd 524390
Medicorp Technologies India Ltd (Merged) 532108 MEDICOTECH
Nagarjuna Drugs Ltd 530064
Nagarjuna Nature Base Ltd 40353
Nalin Chemicals Ltd 531292
Natco Laboratories Ltd (Merged) 500299 NATCOLABS
Neuland Laboratories Ltd 524558 NEULANDLAB
NGL Fine Chem Ltd 524774 NGLFINE
Nutraplus India Ltd 524764
Oxygenta Pharmaceutical Ltd 524636
Paam Drugs & Pharmaceuticals Ltd 524462 PAAMDRUG
Pan India Drugs & Chemicals Ltd 524560
Panchsheel Organics Ltd 531726 PANCHSHEEL
Par Drugs & Chemicals Ltd 535341 PAR
Parabolic Drugs Ltd 533211 PARABDRUGS
Parmax Pharma Ltd 540359
Pharmed Chemicals Ltd 524733
Piramal Phytocare Ltd(Merged) 532979 PIRPHYTO
Plama Laboratories Ltd (Merged) 524798
Pradeep Drug Company Ltd (Merged) 524246
Ratna Drugs Ltd 524382
Regent Chemicals Ltd 506989
Richline Pharma Ltd 524460
Roopa Industries Ltd 530991
Rupal Chemical Industries Ltd (Merged) 524705
Rupangi Impex Ltd (Wound-up) 512606 RUPANGIMPX
Samrat Pharmachem Ltd 530125
Sharvani Pharmaceuticals Ltd 40159
Shasun Pharmaceuticals Ltd(Merged) 524552 SHASUNPHAR
Shelter Pharma Ltd 543963
Shilpax Laboratories Ltd 524482
Shrishma Fine Chemicals (Karnataka) Ltd 507000
Siris Ltd 524746 SIRIS
Smruthi Organics Ltd 540686
SMS Pharmaceuticals Ltd 532815 SMSPHARMA
Southern Herbals Ltd 500395 SOUTHNHERB
Sri Chakra Remedies Ltd (Merged) 507484
Stellar Drugs Ltd 524612
Sterling Basic Organics Ltd 524644
Swet-Chem Antibiotics Ltd 531186
Targof Pure Drugs Ltd 40230
Teem Laboratories Ltd 507761
Tyche Industries Ltd 532384
Umedix India Ltd 524822
Venkat Pharma Ltd 532093
Venmax Drugs & Pharmaceuticals Ltd 531015
Vera Laboratories Ltd (Merged) 40228
Vilin Bio Med Ltd 78871 VILINBIO
Vitara Chemicals Ltd 524646 VITARACHEM
Vorin Laboratories Ltd (Merged) 524508
Zora Pharma Ltd(merged) 524438
Zyden Gentec Ltd 530091

Share Holding

Category No. of shares Percentage
Total Foreign 28162 0.22
Total Institutions 77920 0.62
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 649636 5.16
Total Promoters 6753425 53.65
Total Public & others 5079857 40.35
Total 12589000 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Lactose (India) Ltd

Lactose (India) Ltd was incorporated on March 1991 as a Public Limited Company in the Vadodara district of Gujarat. The company is engaged in the manufacturing and trading of pharmaceutical products. They offer edible and pharmaceutical grade lactose, which is used as an ingredient in pharmaceutical products, as well as in the dairy, food, confectionery, and beverage industries. The company also manufactures dairy whitener, dairy calcium, whey powder, casein, caseinate, butter, and ghee. Further, they engage in the contract manufacture of pharmaceutical products. The company is having their manufacturing facilities located at Vadodara in Gujarat. This state of art manufacturing facilities for the manufacture of pharmaceutical formulations is in compliance with all international standards. The manufacturing facilities include wet granulation, Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments. The company is well backed up by its excellent network of indenting agents in India i.e. Mumbai, Delhi, Chennai, Bangalore, Calcutta, Hyderabad and Ahmedabad. The company set up a project to manufacture lactose IP/BP grade, an import substitute, with an installed capacity of 465 TPA at an estimated cost of Rs 4.5 crore. The unit was commissioned by Alfa Laval, Pune, a subsidiary of Alfa Laval, Sweden. In January 1994, the company commenced commercial production of Lactose. In the year 1994, the company undertook an expansion and forward integration programme involving the capacity expansion of lactose from 465 tpa to 1500 tpa. They also set up of a pharmaceutical formulation plant with three sections, namely capsule section, tablet section and indictable section. During the year 1995-96, the company started processing sweetened condenced milk for domestic supply and acid casein for exports. They had started the job work of condensed milk casein powder. During the year 2004-05, the company streamlined their pharmaceutical plant and entered into long-term contract manufacturing for one of the leading multinational company. They invested substantially in upgrading and renovating the Pharmaceutical facilities as per the requirement of the new Schedule M, as per the directives from the Food and Drug Administration. Also, they started a new equipment manufacture, assemble and export for Projects division in Kandla SEZ (Special Economic Zone). During the year 2006-07, the company undertook major expansion programme at their existing production site for manufacturing of value added product 'LACTULOSE' which is a forward integration of their existing product 'LACTOSE'. During the year 2007-08, the company successfully implemented the task undertaken last year and commissioned the new liquid orals division. During the year 2008-09, the company started manufacturing of Liquid Formulations. The Company in 2010, formed strategic alliance with Kerry Group of Ireland for contract manufacturing Of lactose 10,000 Mt / Annum. It started manufacturing for Dr Reddy's for their Liquid Oral Bottles in 2015. In 2016, it started Lactulose Manufacturing API Plant. In 2022, it started own marketing & sales of Lactose Monohydrate under the banner of Lactose (India) Limited. The Company in 2023, launched production of Lactulose with state of art manufacturing facility. The Plant produces Lactulose Concentrate USP & Lactulose Solution USP/EP. It broadened the horizons by getting into contract manufacturing of Tablets, Liquid orals & Manufacturing of Finished Formulations.

Lactose (India) Ltd Chairman Speech

Dear Shareholder

Sub: Green Initiative in corporate Governance-Electronic mode of service of Documents

The Ministry of Corporate affairs, Government of India, has by circular no 17/2011 dated 21st April 2011 and 18/2011 dated 29th April,2011 respectively, clarified that a company will have complied with the provisions of the companies act, 1956, if service of notice(s) / document(s) on its shareholders has been made through electronic mode. This initiative by the government is indeed commendable and your company supports the same. We are sure, that as a responsible shareholder, you too will support this initiative. By registering yourself with the company for e-communication, you will be able to receive such notice(s) / document(s) etc. promptly and without loss in postal transit.

It is proposed that henceforth documents like Notices of Meetings, annual Reports, Directors Report, Auditors Report and other shareholder communication will be sent electronically to the email address provided by you and made available to the Company by the Depositories viz, NSDL / CDSL. As and when there are changes in your email address, you are requested to keep your Depository Participant (DP) informed of the same.

For shares held in Physical form, shareholders can either register their email address with the Company at investor.lactose@gmail.com mentioning their name(s) and Folio no. or return this Letter duly filled in to the Company’s Registrar & Transfer Agent.

Kindly note that if you still wish to get a hard copy of the above documents, the Company will send the same, free of cost, upon receipt of a request from you.

Thanking you Yours sincerely,

For Lactose (India) Limited

Atul Maheshwari

Managing Director

   

Lactose (India) Ltd Company History

Lactose (India) Ltd was incorporated on March 1991 as a Public Limited Company in the Vadodara district of Gujarat. The company is engaged in the manufacturing and trading of pharmaceutical products. They offer edible and pharmaceutical grade lactose, which is used as an ingredient in pharmaceutical products, as well as in the dairy, food, confectionery, and beverage industries. The company also manufactures dairy whitener, dairy calcium, whey powder, casein, caseinate, butter, and ghee. Further, they engage in the contract manufacture of pharmaceutical products. The company is having their manufacturing facilities located at Vadodara in Gujarat. This state of art manufacturing facilities for the manufacture of pharmaceutical formulations is in compliance with all international standards. The manufacturing facilities include wet granulation, Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments. The company is well backed up by its excellent network of indenting agents in India i.e. Mumbai, Delhi, Chennai, Bangalore, Calcutta, Hyderabad and Ahmedabad. The company set up a project to manufacture lactose IP/BP grade, an import substitute, with an installed capacity of 465 TPA at an estimated cost of Rs 4.5 crore. The unit was commissioned by Alfa Laval, Pune, a subsidiary of Alfa Laval, Sweden. In January 1994, the company commenced commercial production of Lactose. In the year 1994, the company undertook an expansion and forward integration programme involving the capacity expansion of lactose from 465 tpa to 1500 tpa. They also set up of a pharmaceutical formulation plant with three sections, namely capsule section, tablet section and indictable section. During the year 1995-96, the company started processing sweetened condenced milk for domestic supply and acid casein for exports. They had started the job work of condensed milk casein powder. During the year 2004-05, the company streamlined their pharmaceutical plant and entered into long-term contract manufacturing for one of the leading multinational company. They invested substantially in upgrading and renovating the Pharmaceutical facilities as per the requirement of the new Schedule M, as per the directives from the Food and Drug Administration. Also, they started a new equipment manufacture, assemble and export for Projects division in Kandla SEZ (Special Economic Zone). During the year 2006-07, the company undertook major expansion programme at their existing production site for manufacturing of value added product 'LACTULOSE' which is a forward integration of their existing product 'LACTOSE'. During the year 2007-08, the company successfully implemented the task undertaken last year and commissioned the new liquid orals division. During the year 2008-09, the company started manufacturing of Liquid Formulations. The Company in 2010, formed strategic alliance with Kerry Group of Ireland for contract manufacturing Of lactose 10,000 Mt / Annum. It started manufacturing for Dr Reddy's for their Liquid Oral Bottles in 2015. In 2016, it started Lactulose Manufacturing API Plant. In 2022, it started own marketing & sales of Lactose Monohydrate under the banner of Lactose (India) Limited. The Company in 2023, launched production of Lactulose with state of art manufacturing facility. The Plant produces Lactulose Concentrate USP & Lactulose Solution USP/EP. It broadened the horizons by getting into contract manufacturing of Tablets, Liquid orals & Manufacturing of Finished Formulations.

Lactose (India) Ltd Directors Reports

To,

The Members,

Your Directors proudly present to you the 32nd Annual Report of the Company together with the Audited Statement of the Accounts for the Financial year ended on 31st March, 2023.

1. FINANCIAL STATEMENT:

(Rs. In Lakhs)
Particulars 2022-2023 2021-2022
Operating and other Income 6,652.57 4,651.76
Total Expense 6,506.11 4,335.13
Profit before Tax 146.45 316.63
Provision for Current Tax 24.45 56.94
Deferred Tax 7.66 14.56
Taxation of Earlier Years (6.52) -
Profit After Tax 127.64 238.08

2. DIVIDENDS:

The Board of Directors of your Company do not recommend any Dividend on equity shares for the FY 2022-2023.

3. REVIEW OF OPERATIONS:

During the year under review, the revenue of the Company has increased to Rs. 6,579.63 lakhs as compared to Rs. 4,593.90 lakhs in the corresponding previous year.

The Company earned net profit of Rs. 127.64 lakhs as compared to net profit of Rs. 238.08 lakhs in the corresponding previous year.

Earning per share is Rs. 0.96 for the current year and Rs 2.10 for the previous year

4. TRANSFER TO RESERVE:

The Company has not transferred amount to reserves during the Financial Year 2022-23.

5. DEPOSITS:

The details of deposits as covered under Chapter V of the Act are as under:

Deposits accepted during the year Nil
a) Remained unpaid or unclaimed as at the end of the year Nil
b) Whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases and the total amount involved: Nil
At the beginning of the year
(i) Maximum during the year
(ii) At the end of the year
c) The details of deposits which are not in compliance with the requirements of Chapter Nil

6. NATURE OF BUSINESS:

The company is engaged in the business of manufacturers, manufacturer representatives, producers, processors, refiners, consignors, consignees, factors, agents, exporters, importers and distributors of all classes, kinds, types and nature of:

I. Foods whether finished, semi-finished, processed and unprocessed.

II. Milk cream ice-cream, curd, butter milk, paneer, cheese, sweetmeats, chocolates and other dairy products.

III. Pharmaceuticals, drugs bulk drugs, medicines.

IV. Chemicals, chemical products, chemical compounds, derivatives and intermediates.

7. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES:

The Company does not have subsidiary, Joint Venture and Associate companies.

No company has become or ceased to be the Company's subsidiaries, joint ventures or associate companies during the year under review.

8. COMPLIANCE WITH SECRETARIAL STANDARDS:

The Board of Directors affirm that the Company has complied with the applicable Secretarial Standards ("SS") issued by the Institute of Company Secretaries of India relating to the meetings of the Board and its committees as well as the general meetings (SS-1 and SS-2) respectively, which have mandatory application during the year under review.

9. SHARE CAPITAL:

The details of Share capital of the Company are as under:

As on 31st March, 2023

As on 31st March, 2022

Particulars Number of Shares (Rs.in Lakhs) Number of Shares (Rs in Lakhs)
Authorised Capital: Equity Shares of Rs 10/- each 1,50,00,000 1500.00 1,50,00,000 1500.00
Issued, Subscribed & Paid-Up Capital: Equity Shares of Rs 10/- each 1,25,89,000 1258.90 1,25,89,000 1258.90

10. DIRECTORS AND KEY MANAGERIAL PERSONNEL:

At the 32nd Annual General Meeting ("AGM") of the Company and in accordance with the applicable provisions of Section 152 of the Act and the Articles of Association of the Company, Mrs. Sangita Maheshwari (DIN: 00369898) is liable to retire by rotation and being eligible, offers herself - for re-appointment as Director- of the Company.

Necessary resolution- for her re-appointment is included in the Notice of 32nd AGM for seeking approval of the members of the Company.

11. DECLARATION BY AN INDEPENDENT DIRECTOR(S):

All Independent Directors have given declarations that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

12. FORMAL ANNUAL BOARD EVALUATION:

The annual evaluation process of the Board of Directors, individual Directors and Committees was conducted in accordance with the provision of the Act and the SEBI Listing Regulations.

The Board evaluated its performance after seeking inputs from all the directors on the basis of criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc. The performance of the Committees was evaluated by the Board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc. The above criteria are as provided in the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India.

The evaluation was done in accordance with the framework and criteria laid down by the NRC. Further, at a separate meeting, the Independent Directors evaluated performance of Non-Independent Directors, Board as a whole and of the Chairman of the Board.

13. MANAGEMENT DISCUSSION & ANALYSIS REPORTS:

The Management Discussion and Analysis of financial condition, including the results of operations of the Company for the year under review as required under Regulation 34(2)(e) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is provided as a separate section forming part of the Annual Report.

14. BOARD MEETINGS:

During FY 2022-23, 07 (Seven) Board Meetings were conveyed and held by the Company. The details of which are given in the Corporate Governance Report. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

15. SEPARATE MEETING OF INDEPENDENT DIRECTORS:

Pursuant to Schedule IV of the Companies Act, 2013 and the Rules made thereunder and Regulation 25 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate meeting of Independent Directors was held on 31st March, 2023 during the financial year 2022-23, without the attendance of Non-Independent Directors and Members of the Management.

The Independent Directors reviewed performance of Non-Independent Directors, Chairman of the Company and the performance of the Board as a whole. The Independent Directors also discussed the quality, quantity and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties. The feedback of the Meeting was shared with the Chairman of the Company.

16. NOMINATION AND REMUNERATION POLICY:

Pursuant to Provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and on the recommendation of the Nomination & Remuneration committee the Board has adopted policy for selection and appointment of Directors, Senior Management and their remuneration. The details of Remuneration Policy is stated in the Corporate Governance Report. The Nomination and Remuneration Policy is posted on the website of the Company.

The web link for the same is: https://www.

lactoseindialimited.com/policv.php

17. STATUTORY AUDIT:

At the Annual General Meeting of the Company held on 17th June, 2022, M/s. C A S & Co., Chartered Accountants, were appointed as statutory auditors of the Company for a term of five years [i.e., till the conclusion of 36th Annual General Meeting.] The requirement to place the matter relating to appointment of auditors for ratification by members at every AGM has been done away by the Companies (Amendment) Act, 2017 with effect from 07th May, 2018. Accordingly, no resolution is being proposed for ratification of appointment of Statutory auditors at the ensuing AGM.

The Auditors Report for the financial year 2022-23, does not contain any qualification, reservation or adverse remark.

The Notes on Accounts referred to in the Auditors' Report are self-explanatory and do not call for any further comments.

18. SECRETARIAL AUDIT:

Pursuant to the provisions of Section 204 of the Act and the Companies (Appointment and Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. Jajodia & Co., a firm of Company Secretaries in Practice to undertake the Secretarial Audit of the Company for the financial year ended 31st March, 2023. The Report of the Secretarial Audit is annexed as "Annexure A" to this Board's Report.

The Secretarial Audit Report does not contain any qualification, reservation, adverse remarks and disclaimer.

The Company is in compliance with the Secretarial Standards specified by the Institute of Company Secretaries of India.

19. INTERNAL FINANCIAL CONTROL SYSTEM AND THEIR ADEQUACY:

The Act introduced regulations with focus on control and compliance requirements, in light of which, the Company has laid down internal financial controls across various processes prevalent in the organization. These controls have been established at the entity as well as process level and are designed to ensure compliance to internal control requirements, regulatory compliance and enable appropriate recording of financial and operational information. The Company has reviewed the effectiveness of its internal financial controls by adopting a systematic approach to assess the design and its operating effectiveness.

During the financial year, such controls were tested and no reportable material weakness in the design or operation was observed. The Company is following all the applicable Accounting Standards for properly maintaining the books of accounts and reporting financial statements.

20. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

The Company has a vigil mechanism to deal with instance of fraud and mismanagement, if any. The policy is placed on the website of the Company. The web link for the same is:- https://www.lactoseindialimited.com/policv.php

21. ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE:

The information required under Section 134 (3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014, with respect to conservation of energy, technology absorption and foreign exchange earnings/outgo is given hereto and forms a part of this report as an "Annexure B".

22. TECHNOLOGY ABSORPTION, ADAPTATION AND INNOVATION:

Energy conservation is not only a national priority but also a key value driver for your Company. Employees are also encouraged to give suggestion that will result in energy saving.

As prescribed under the Section 134 (3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 is not applicable, as there is no technology absorption, adaptation and innovation made by your Company. However, it has been the endeavor of the Company to continuously upgrade & standardize its products.

23. FOREIGN CURRENCY EARNING AND OUTGO:

Sr No. Particulars Rs. In Lakhs
i) CIF Value of Imports 2061.12
ii) Expenditure in foreign currency 23.91
iii) Foreign Exchange earned 1035.46

24. PARTICULARS OF EMPLOYEES:

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are provided in the Annual Report and is marked as "Annexure C" to this Report.

25. EXTRACT OF ANNUAL RETURN:

Pursuant to Section 92 of the Companies Act, 2013 ("Act") read with Rule 12 of The Companies (Management and Administration) Rules, 2014 and Section 134 (3) (a), the copy of Annual Return can be accessed on the website of the Company at www.lactoseindialimited.com

26. RELATED PARTY TRANSACTIONS:

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. There are no materially significant related party transactions made by the Company with promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

27. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS BY THE COMPANY UNDER SECTION 186:

The details of Loan, Guarantees and Investments made by the Company under the provisions of Section 186 of the Companies Act, 2013 are provided in the notes to the Financial Statements.

28. SAFETY, HEALTH AND ENVIRONMENT:

Your Company recognizes its role in health and safety, as well as its responsibility towards environment and society. Infact, your Company's goals are: no accidents, no injuries to people and no damage to environment. Safety and security of personnel, assets and environmental protection are also on top of the agenda of the Company at its manufacturing facilities.

Clean environment and sustainable development integrated with the business objective is the focus of operations of the Company. The projects and activities are planned and designed with environment protection as an integral part to ensure a safe and clean environment for sustainable development.

29. DIRECTORS' RESPONSIBILTY STATEMENT AS REQUIRED UNDER SECTION 134(3)(c) OF THE COMPANIES ACT, 2013:

To the best of knowledge and belief and according to the information and explanation obtained by them, your Directors make the following statements in terms of Section 134(3)(c) of the Act.

a) That in the preparation of the annual financial statements, the applicable accounting standards

have been followed along with proper explanation relating to material departures, if any;

b) That such accounting policies as mentioned in Notes to the Financial Statements have been selected and applied consistently and judgments have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at 31st March, 2023 and of the profit or loss of the company for the year ended on that date;

c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

d) That the annual financial statements have been prepared on a going concern basis;

e) That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively.

f) That systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

30. CORPORATE GOVERNANCE:

As per the SEBI(Listing Obligation and Disclosure Requirements) Regulation, 2015 the Company has prepared a report on Corporate Governance together with a certificate from the Company's Auditors confirming Compliance is set out in the "Annexure D" forming the part of this Annual Report.

DISCLOSURES:

AUDIT COMMITTEE

The Audit Committee comprises Independent Directors namely Mr. Gopal. K. Sarda (Chairman), Mr. Pramod Kalani and Mr. Dhaval Jayant Soni as other members. The Audit Committee played an important role during the year. It co-ordinates with the Statutory Auditors, Internal Auditors and other key personnel of the Company and has rendered guidance in the areas of internal audit and control, finance and accounts. All the recommendations made by the Audit Committee were accepted by the Board. During FY 2022-23, 05 (Five) Audit Committee's Meetings were conveyed and held by the Company. The details of which are given in the Corporate Governance Report.

STAKEHOLDERS RELATIONSHIP COMMITTEE:

The Stakeholders Relationship Committee comprises Independent Directors namely Mr. Gopal. K. Sarda (Chairman), Mr. Pramod Kalani and Mr. Dhaval Jayant Soni as other members. During FY 2022-23, 4 (Four) Stakeholders Relationship Committee's Meetings were conveyed and held by the Company. The details of which are given in the Corporate Governance Report. With the compulsory dematerialization of the Company's shares and electronic mode of transfers, postal dispatches which led to usual complaints, have been minimized.

NOMINATION & REMUNERATION COMMITTEE:

The Nomination and Remuneration Committee comprises Independent Directors namely Mr. Gopal. K. Sarda (Chairman), Mr. Pramod Kalani and Mr. Dhaval Jayant Soni as other members. During FY 2022-23, 01 (One) Nomination & Remuneration Committee's Meetings were conveyed and held by the Company. The details of which are given in the Corporate Governance Report. The Nomination and Remuneration Committee recommends to the Board the suitability of candidates for appointment as Key Managerial Personnel, Directors and the remuneration packages payable to them and other employees.

31. CORPORATE SOCIAL RESPONSIBILITY ("CSR"):

During FY 2022-23, Corporate Social Responsibility is not applicable to the company.

32. PREVENTION OF SEXUAL HARASSMENT POLICY:

The Company has in place Prevention of Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The following is a summary of sexual harassment complaints received and disposed of during the year 2022-23:

a) No. of complaints received: Nil

b) No. of complaints disposed of: N.A.

33. HUMAN RESOURCES AND INDUSTRIAL RELATIONS:

Industrial Relations continued to be harmonious throughout the year under review. Many initiatives have been taken to support business through organizational efficiency, process change support and various employee engagement programs which have helped the Organization achieve higher productivity levels.

34. MATERIAL CHANGES:

During the year, there are no other material changes and commitments, affecting the financial position of the Company, which have occurred between the end of the financial year of the Company i.e. 31st March, 2023 to which these financial statements relate and date of this report.

35. RISK MANAGEMENT POLICY:

As per the Act, and as part of good corporate governance the Company has constituted the Risk Management Committee. The Committee has laid down the procedures to inform the Board about the risk assessment and minimization procedures and the Board shall be responsible for framing, implementing and monitoring the risk management plan and policy for the Company.

The main objective of this policy is to ensure sustainable business growth with stability and to promote a proactive approach in reporting, evaluating and resolving risks associated with the business. In order to achieve the key objective, the policy establishes a structured and disciplined approach to Risk Management, in order to guide decisions on risk related issues.

The Committee reviewed the risk trend, exposure and potential impact analysis carried out by the management. It was specifically confirmed to the Committee by the MD and the CFO that the mitigation plans are finalised and up to date, owners are identified and the progress of mitigation actions are monitored.

36. CODE OF CONDUCT:

Your Company has established a Code of Conduct and Code of Fair Disclosures for Prohibition of Insider Trading ("Code of Conduct" or "Code") which is applicable to the Employees, Directors, designated persons, immediate relatives of designated persons and connected persons of the Company. The Code lays down the standard of conduct, which is expected to be followed by the Directors and employees in their business dealings, and in particular, on matters relating to integrity in the workplace, dealing with stakeholders and in business practices. All the Board Members and the Senior Management employees have confirmed compliance with the Code.

The Code is available on website of the Company at www. lactoseindialimited.com

37. SIGNIFICANT OR MATERIAL ORDERS AGAINST COMPANY:

No significant and material orders were passed by the regulators or courts or tribunals impacting the going concern status and your Company's operation in future.

38. APPRECIATION:

Your Directors take this opportunity to convey their deep sense of gratitude for valuable assistance and Co-operation extended to the Company by all valued customers and bankers of the Company.

Your Directors also wish to place on record their sincere appreciation for the valued contribution, unstinted efforts by the employees at all levels which contributed, in no small measure, to the progress and the high performance of the Company during the year under review.

For and on behalf of the Board
For Lactose (India) Limited
Sd/- Sd/-
(Atul Maheshwari) (Sangita Maheshwari)
Managing Director Whole-time Director & CFO
Date: 27th July, 2023
Place: Mumbai
Regd. Office:
Survey No. 5,6 &7A Village Poicha (Rania),
Savli Vadodara, Gujarat 391780
Tel No. : +91-22-24117030
CIN : L15201GJ1991PLC015186
Website : www.lactoseindialimited.com
E-mail id : lil@lactoseindialimited.com

   

Lactose (India) Ltd Company Background

Atul MaheshwariAtul Maheshwari
Incorporation Year1991
Registered OfficeSurvey No 6,Village Poicha (Rania) Savli
Vadodara,Gujarat-391780
Telephone91-02667-244308/244729,Managing Director
Fax91-02667-840397
Company Secretary
AuditorCAS & Co
Face Value10
Market Lot1
ListingBSE,
RegistrarBigshare Services Pvt Ltd
Office No 56-2 ,Pinnacle Busine.Park,Mahakali Caves Road ,Mumbai - 400093

Lactose (India) Ltd Company Management

Director NameDirector DesignationYear
Atul MaheshwariChairman & Managing Director2023
S M MaheshwariWhole Time Director & CFO2023
Pramod KalaniIndependent Non Exe. Director2023
G K SardaIndependent Non Exe. Director2023
Dhaval J SoniIndependent Non Exe. Director2023

Lactose (India) Ltd Listing Information

Lactose (India) Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Conversion ChargesNA00030.9976
Pharmaceutical ProductsNA0008.3446
Manufacturing ConsiderationNA0000.5777
Scrap SalesNA0000.092
MEIS Export incentivesNA0000.0366
AdjustmentNA0000
Lactose Monohydrate IP/BPNA0000
Lactose PowderMT0000
MachineryNA0000
Other Operating RevenueNA0000
OthersNA0000
Sweet WheyKg0000
Job Work ChargesNA0000
Crude Lactose & Others-TradedMT0000
LactuloseLtr0000
SalesNA0000
Liquid FormulationsLtr0000
Low Density PolyethyleneNA0000
Low Density Polyethylene-TradeNA0000
Nergys SachetsNo0000
SachetsNo0000
Strength Plus SachetsNo0000
FabricMtr0000

Contact us Contact us